Philip Morris to Take $220 Million Loss on Sale of Inhaled-Medicine Unit

Posted by | ISLE Brew | 0 |

Philip Morris said it expects to record a loss on the sale of its inhaled-therapeutics unit to Molex Asia Holdings as it retools its pharmaceutical business.

Philip Morris said it expects to record a loss on the sale of its inhaled-therapeutics unit to Molex Asia Holdings as it retools its pharmaceutical business. WSJ.com: US Business